Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F23%3A00579002" target="_blank" >RIV/61389005:_____/23:00579002 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/s00259-023-06333-x" target="_blank" >https://doi.org/10.1007/s00259-023-06333-x</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report

Popis výsledku v původním jazyce

Puromycin is a relevant scafold for the development of a radiopharmaceutical that will allow the quantifcation of protein synthesis non-invasively through nuclear based imaging techniques. A signifcant clinical application of radiolabeled puromycin depends on the visualization of mycobacterial protein synthesis for future clinical investigations of tuberculous lesions. To date, no systematic characterization of a puromycin-based radiopharmaceuticals as potential in vivo infection imaging agents has been reported. Therefore, this study will address selectivity, sensitivity, and accuracy of [68Ga]Ga-DOTA-puromycin-micro-positron emission tomography combined with magnetic resonance imaging (microPET/MRI) imaging to determine the role and value of this technique to detect mycobacterial infection in vivo.

Název v anglickém jazyce

Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report

Popis výsledku anglicky

Puromycin is a relevant scafold for the development of a radiopharmaceutical that will allow the quantifcation of protein synthesis non-invasively through nuclear based imaging techniques. A signifcant clinical application of radiolabeled puromycin depends on the visualization of mycobacterial protein synthesis for future clinical investigations of tuberculous lesions. To date, no systematic characterization of a puromycin-based radiopharmaceuticals as potential in vivo infection imaging agents has been reported. Therefore, this study will address selectivity, sensitivity, and accuracy of [68Ga]Ga-DOTA-puromycin-micro-positron emission tomography combined with magnetic resonance imaging (microPET/MRI) imaging to determine the role and value of this technique to detect mycobacterial infection in vivo.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů